About Orphazyme

Company Description

Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.

We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC).

In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.

Year founded

2009

Headquarters

Ole Maaløes Vej 3, 2200 Copenhagen – Denmark

Shareholder information

Shares outstanding

35,312,241

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Copenhagen

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.